Analysts’ upgrades for Wednesday, November 15th:

ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $30.00 target price on the stock. According to Zacks, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. “

Comstock Holding Companies (NASDAQ:CHCI) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

City Office REIT (NYSE:CIO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “City Office REIT, Inc. is a real estate investment trust. It focuses on acquiring, owning, and operating office properties in the United States. The Company invests in properties located in metropolitan areas in the Southern and Western United States. City Office REIT, Inc. is based in Vancouver, Canada. “

C&J Energy Services (NYSE:CJ) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “C&J Energy Services, Inc. is a provider of on-shore well construction, well completion, well support and other complementary oilfield services to oil and gas exploration and production companies. It offers hydraulic fracturing, cased-hole wireline, coiled tubing, cementing, rig services, fluids management services and other special well site services. The company operates primarily in United States and Western Canada. C&J Energy Services, Inc. is based in Houston, United States. “

Caladrius Biosciences (NASDAQ:CLBS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $3.25 price target on the stock. According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “

Cumulus Media (NASDAQ:CMLS) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $0.25 target price on the stock. According to Zacks, “Cumulus Media, Inc. is a radio broadcasting company focused on acquiring, operating and developing radio stations in mid-size radio markets in the United States. They provide sales and marketing services under local marketing, management and consulting agreements. “

Concert Pharmaceuticals (NASDAQ:CNCE) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “

Crocs (NASDAQ:CROX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Crocs, Inc. is a world leader in innovative casual footwear for men, women and children. Crocs offers a broad portfolio of all-season products, while remaining true to its core molded footwear heritage. All Crocs™ shoes feature Croslite™ material, a proprietary, revolutionary technology that gives each pair of shoes the soft, comfortable, lightweight, non-marking and odor-resistant qualities that Crocs fans have known and love. Crocs celebrates the fun of being a little different and encourages fans to Find Your Fun in every colorful pair of shoes. Crocs has sold more than 300 million pairs of shoes in more than 90 countries around the world. “

Cemex S.A.B. de C.V. (NYSE:CX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CEMEX is one of the largest cement companies in the world, with close to 78 million metric tons of production capacity. Through operating subsidiaries in four continents, they are engaged in the production, distribution, marketing and sale of cement, ready-mix concrete, aggregates and clinker. They are also the world’s leading producer of white cement and the world’s largest trader of cement and clinker. “

First Industrial Realty Trust (NYSE:FR) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

Japan Airlines Co. (OTCMKTS:JAPSY) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

Liberty Global PLC (NASDAQ:LILAK) was upgraded by analysts at ValuEngine from a sell rating to a hold rating.

Anglo Amer Adr (OTCMKTS:NGLOY) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

Children’s Place, Inc. (The) (NASDAQ:PLCE) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

Quest Resource Holding Corporation. (NASDAQ:QRHC) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating.

YY (NASDAQ:YY) was upgraded by analysts at ValuEngine from a buy rating to a strong-buy rating.

Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.